A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-05

Study Completion Date

2023-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study of NicaPlant® is conducted in patients who have a subarachnoid haemorrhage. Patients will be randomized in two treatment groups. Both groups will receive the standard of care and the investigational group will receive in addition NicaPlant®. NicaPlant® is tested to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial

NCT06329635

Aneurysmal Subarachnoid Hemorrhage Vasospasm

RECRUITING NA

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

NCT02560532

Aneurysmal Subarachnoid Hemorrhage

COMPLETED PHASE2

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

NCT00558311

Aneurysmal Subarachnoid Hemorrhage

COMPLETED PHASE3

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

NCT00487461

Aneurysmal Subarachnoid Hemorrhage Cerebral Vasospasm

TERMINATED NA

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

NCT00839449

Subarachnoid Hemorrhage Cerebral Vasospasm

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a safety, tolerability, efficacy and pharmacokinetic study of NicaPlant® in subarachnoid haemorrhage patients involving two treatment groups. Both treatment groups will receive standard of care and patients randomised to the investigational group will receive in addition NicaPlant® .

NicaPlant® is a nicardipine modified-release formulation. It is presented in the form of a rod-shaped implant with a 4 mg nicardipine load. Following aneurysm clip ligation, 10 NicaPlant® implants will be placed into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aneurysmal Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

The clinical trial is defined as a single-blind study. For ethical reasons, no placebo implants will be used and therefore the surgeon cannot be blinded. All investigators/surgeons who have not been involved in the operation of a patient will remain blinded for this particular patient.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NicaPlant®

10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.

In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.

Group Type EXPERIMENTAL

Nicardipine

Intervention Type DRUG

10 NicaPlant® implants releasing 4 mg nicardipine each.

Standard of care

Intervention Type OTHER

Both arms receive the usual standard of care.

Control

Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.

Group Type OTHER

Standard of care

Intervention Type OTHER

Both arms receive the usual standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicardipine

10 NicaPlant® implants releasing 4 mg nicardipine each.

Intervention Type DRUG

Standard of care

Both arms receive the usual standard of care.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NicaPlant®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent obtained according to the Country regulation.
* Male or female patients aged 18 to 75 years (inclusive).
* World Federation of Neurological Surgeons (WFNS) grade III-IV.
* Ruptured saccular aneurysm, confirmed by angiography.
* Onset of aSAH clinical symptoms within the preceding 48 hours.
* Treatment of aneurysm via surgical clip ligation within 72 hours of aSAH is achievable.
* Female patients of child-bearing potential must have a negative pregnancy test (urine or serum) at screening and must agree to use adequate birth control up to 12 weeks after implantation of the study drug. Female patients are considered to be not of child-bearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 2 years without a natural menstrual cycle. Male patients must agree to use adequate birth control up to 12 weeks after implantation of the study drug.

Exclusion Criteria

* SAH due to other causes (e.g. trauma, fusiform or mycotic aneurysm).
* World Federation of Neurosurgery (WFNS) grade I, II and V patients.
* Pregnant or Lactating Women.
* Intraventricular or intracerebral blood, in the absence of subarachnoid blood.
* Treatment of aneurysm via endovascular embolisation.
* Presence of moderate or severe vasospasm on screening angiography.
* Any known or CT /MRI evidence of previous major cerebral damage
* Evidence of a cerebral infarction with neurological deficit on pre-treatment CT/MRI.
* History of malignant disease (except for non-melanoma skin cancer) within the previous 5 years or any history of malignant brain tumours or brain metastasis.
* Patients who have received an investigational product or participated in another interventional clinical study within 30 days prior to randomisation.
* Patients with known allergy for Poly(D,L-lactide-co-glycolide) (PLGA) or nicardipine.
* Major complication during aneurysm repair such as, but not limited to, massive intraoperative haemorrhage, brain swelling, or inability to secure the ruptured aneurysm.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No